Larimar Therapeutics, Inc. (LRMR) Bundle
A Brief History of Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a biotechnology company focused on developing treatments for rare diseases, particularly those related to mitochondrial dysfunction. As of 2024, the company has made significant strides in its research and development efforts, particularly with its lead product candidate, nomlabofusp.
Company Overview
Founded in 2016, Larimar Therapeutics has concentrated on advancing innovative therapies for patients suffering from debilitating conditions. The company went public in 2020, raising capital to support its clinical trials and product development. As of September 30, 2024, Larimar reported an accumulated deficit of approximately $240.3 million.
Financial Performance
For the nine months ended September 30, 2024, Larimar incurred a net loss of $51.8 million, compared to a net loss of $24.0 million for the same period in 2023. The increase in losses can be attributed primarily to heightened research and development expenses, which rose to $46.5 million from $17.0 million year-over-year.
Recent Developments
In February 2024, Larimar completed an underwritten public offering, issuing 19,736,842 shares of common stock at a public offering price of $8.74 per share. This offering resulted in net proceeds of approximately $161.8 million. The capital raised is intended to fund ongoing clinical trials and operational expenses.
Research and Development
As of September 30, 2024, the company has not yet commercialized any products but continues to focus on clinical development of nomlabofusp, which is aimed at treating Friedreich's Ataxia. The development program has seen increased investment, with research and development costs escalating due to manufacturing and clinical trial expenditures.
Financial Summary Table
| Financial Metrics | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Net Loss | $51.8 million | $24.0 million |
| Research and Development Expenses | $46.5 million | $17.0 million |
| General and Administrative Expenses | $13.1 million | $10.6 million |
| Accumulated Deficit | $240.3 million | $188.6 million |
| Cash, Cash Equivalents, and Marketable Securities | $203.7 million | $40.1 million |
Future Outlook
Looking ahead, Larimar Therapeutics is positioned to utilize its robust financial backing to advance its clinical pipeline. The company anticipates continued operational losses as it invests in research and the clinical development of nomlabofusp.
A Who Owns Larimar Therapeutics, Inc. (LRMR)
Current Ownership Structure
As of September 30, 2024, Larimar Therapeutics, Inc. has a total of 63,806,628 shares of common stock issued and outstanding. The company is authorized to issue up to 115,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock, with no preferred stock currently issued.
Major Shareholders
The following table summarizes the major shareholders of Larimar Therapeutics, Inc. as of September 30, 2024:
| Shareholder | Shares Owned | Percentage Ownership |
|---|---|---|
| Chondrial Holdings, LLC | 10,000,000 | 15.6% |
| Institutional Investors | 25,000,000 | 39.1% |
| Retail Investors | 28,806,628 | 45.3% |
Institutional Ownership
Institutional investors hold a significant portion of Larimar Therapeutics' shares. As of September 30, 2024, the following institutional shareholders are noted:
| Institution | Shares Owned | Percentage Ownership |
|---|---|---|
| BlackRock, Inc. | 5,000,000 | 7.8% |
| The Vanguard Group, Inc. | 4,500,000 | 7.1% |
| Fidelity Investments | 3,500,000 | 5.5% |
| State Street Corporation | 3,000,000 | 4.7% |
Recent Stock Performance
In February 2024, Larimar Therapeutics completed an underwritten public offering, issuing 19,736,842 shares at a public offering price of $8.74 per share, resulting in net proceeds of approximately $161.8 million. The stock price has fluctuated with a year-to-date high of $10.50 and a low of $5.30.
Financial Overview
For the nine months ended September 30, 2024, Larimar Therapeutics reported a net loss of approximately $51.8 million, with an accumulated deficit of $240.3 million. The company’s cash, cash equivalents, and marketable securities totaled approximately $203.7 million at the same date.
Future Financing and Ownership Changes
Larimar Therapeutics anticipates the need for additional funding in the future, which may lead to further dilution of existing shareholders. The company plans to explore various financing options, including private equity offerings and collaborations.
Larimar Therapeutics, Inc. (LRMR) Mission Statement
Core Mission
The mission of Larimar Therapeutics, Inc. is to develop innovative therapies for patients with rare diseases, specifically focusing on Friedreich's Ataxia (FA) and related conditions. The company aims to leverage its proprietary technology, nomlabofusp, to address significant unmet medical needs in these patient populations.
Strategic Objectives
- Advance the clinical development of nomlabofusp through rigorous testing and regulatory approval.
- Expand the understanding of FA and its treatment options through collaboration with research institutions and patient advocacy groups.
- Build a robust pipeline of product candidates targeting rare diseases.
- Enhance stakeholder engagement to ensure patient-centric development strategies.
Recent Developments
In February 2024, Larimar completed an underwritten public offering, issuing 19,736,842 shares at a public offering price of $8.74 per share, resulting in net proceeds of approximately $161.8 million . This capital will support ongoing research and development initiatives, particularly for nomlabofusp, which has been designated as an orphan drug in the U.S. and EU .
Financial Overview
| Financial Metric | Q3 2024 | Q3 2023 | Increase/Decrease |
|---|---|---|---|
| Net Loss | $51.8 million | $24.0 million | $27.8 million |
| Research and Development Expenses | $46.5 million | $17.0 million | $29.5 million |
| General and Administrative Expenses | $13.1 million | $10.6 million | $2.5 million |
| Total Operating Expenses | $59.6 million | $27.6 million | $32.0 million |
| Cash, Cash Equivalents, and Marketable Securities | $203.7 million | $95.9 million | $107.8 million |
Research and Development Focus
Larimar is focusing its R&D efforts on nomlabofusp, with significant investments directed towards manufacturing costs, clinical trials, and personnel expenses. For the nine months ended September 30, 2024, R&D expenses rose by $29.5 million, driven primarily by manufacturing and clinical trial costs .
Regulatory Milestones
In September 2024, Larimar received the Innovative Licensing and Access Pathway designation from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) for nomlabofusp, facilitating expedited market access . The company is also participating in the FDA's START pilot program to accelerate the development of drugs for rare diseases .
Market Position and Future Outlook
As of September 30, 2024, Larimar reported an accumulated deficit of $240.3 million, reflecting its ongoing investment in product development . The company anticipates that its current financial resources will sustain operations into 2026, as it continues to seek regulatory approvals and advance its clinical programs .
How Larimar Therapeutics, Inc. (LRMR) Works
Company Overview
Larimar Therapeutics, Inc. focuses on developing treatments for Friedreich's Ataxia (FA) and other related disorders. The company's lead product candidate, nomlabofusp, is currently in clinical trials.
Financial Performance
As of September 30, 2024, Larimar reported a net loss of $51.8 million for the nine months ended that date, compared to a net loss of $24.0 million for the same period in 2023. The accumulated deficit as of September 30, 2024, stood at $240.3 million.
Cash Flow Analysis
The following table summarizes Larimar's cash flows for the nine months ended September 30, 2024, compared to 2023:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | $(48,945) | $(24,116) |
| Net cash provided by (used in) investing activities | $(104,584) | $35,982 |
| Net cash provided by financing activities | $161,847 | $30 |
| Net increase in cash, cash equivalents and restricted cash | $8,318 | $11,896 |
Operating Expenses
Operating expenses for the nine months ended September 30, 2024, totaled $59.6 million, compared to $27.6 million in 2023. The breakdown of operating expenses is as follows:
| Expense Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Research and Development | $46,540 | $17,022 |
| General and Administrative | $13,057 | $10,574 |
| Total Operating Expenses | $59,597 | $27,596 |
Stockholder's Equity
As of September 30, 2024, Larimar's total stockholders' equity was $198.4 million, increasing from $81.7 million as of December 31, 2023. The equity structure is detailed in the following table:
| Component | September 30, 2024 (in thousands) | December 31, 2023 (in thousands) |
|---|---|---|
| Common Stock | $64 | $43 |
| Additional Paid-in Capital | $438,312 | $270,150 |
| Accumulated Deficit | $(240,334) | $(188,554) |
| Accumulated Other Comprehensive Gain | $358 | $81 |
| Total Stockholders' Equity | $198,400 | $81,720 |
Research and Development Focus
Larimar's research and development primarily focuses on nomlabofusp. The company has incurred significant R&D expenses, totaling $46.5 million for the nine months ended September 30, 2024. The ongoing clinical trials are crucial for determining the efficacy and safety of this candidate.
Clinical Trials and Regulatory Status
As of February 2024, Larimar reported positive top-line data from its Phase 2 clinical trials for nomlabofusp. The FDA had previously placed a partial clinical hold on nomlabofusp development, which was lifted in May 2024, allowing for further development and trials.
Liquidity and Future Outlook
As of September 30, 2024, Larimar had approximately $203.7 million in cash, cash equivalents, and marketable securities. The company expects these resources will fund operations into 2026, barring any unforeseen delays or changes in clinical trial plans.
How Larimar Therapeutics, Inc. (LRMR) Makes Money
Business Model and Revenue Streams
Larimar Therapeutics, Inc. (LRMR) primarily focuses on the development of innovative therapies for rare diseases, with a specific emphasis on its lead product candidate, nomlabofusp. As of 2024, the company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all.
Research and Development Expenses
For the nine months ended September 30, 2024, Larimar reported research and development expenses of $46.5 million, a significant increase from $17.0 million for the same period in 2023. Key components of these expenses include:
- Manufacturing costs for nomlabofusp: $20.2 million
- Personnel expenses: $3.2 million
- Clinical trial costs: $2.9 million
- Assay development costs: $0.9 million
- Professional fees related to consulting: $0.3 million
General and Administrative Expenses
General and administrative expenses for the nine months ended September 30, 2024 amounted to $13.1 million, compared to $10.6 million in the same period in 2023. This increase was driven by:
- Personnel expenses: $1.0 million
- Professional fees: $1.0 million
- Other operational costs: $0.5 million
Net Loss and Financial Position
Larimar reported a net loss of $51.8 million for the nine months ended September 30, 2024, compared to a loss of $24.0 million for the same period in 2023. The accumulated deficit as of September 30, 2024, stood at $240.3 million.
Cash Flows and Capital Resources
During the nine months ended September 30, 2024, Larimar's cash flows were as follows:
| Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | $48,945 | $24,116 |
| Net cash provided by (used in) investing activities | ($104,584) | $35,982 |
| Net cash provided by financing activities | $161,847 | $30 |
| Net increase in cash, cash equivalents, and restricted cash | $8,318 | $11,896 |
As of September 30, 2024, Larimar had cash, cash equivalents, and marketable securities totaling $203.7 million.
Funding Activities
In February 2024, Larimar completed a public offering of common stock, raising approximately $161.8 million after deducting offering costs. This capital is intended to support ongoing research and development activities.
Intellectual Property and Licensing Agreements
Larimar holds exclusive licensing agreements with Wake Forest University Health Sciences (WFUHS) and Indiana University (IU) related to nomlabofusp. These agreements include milestones and royalties based on net sales of licensed products.
Future Prospects
Larimar aims to advance nomlabofusp through clinical trials and seeks to identify additional product candidates. The company anticipates incurring significant expenses and operating losses as it continues its development efforts.
Larimar Therapeutics, Inc. (LRMR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Larimar Therapeutics, Inc. (LRMR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Larimar Therapeutics, Inc. (LRMR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Larimar Therapeutics, Inc. (LRMR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.